# Deborah Schrag

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/deborah-schrag/

## Facts

| Field | Value |
| --- | --- |
| Citations | 68,053 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 120 |
| i10-index | 364 |
| Last Known Institution | Memorial Sloan Kettering Cancer Center |
| OpenAlex ID | https://openalex.org/A5088893766 |
| ORCID iD | https://orcid.org/0000-0002-4334-5717 |
| Works | 832 |

## Researcher papers

Showing 12 of 14.

- [Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial](https://scholariq.org/papers/symptom-monitoring-with-patient-reported-outcomes-during-routine-cancer/)
- [Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment](https://scholariq.org/papers/overall-survival-results-of-a-trial-assessing-patient-reported-outcomes-for/)
- [AACR Project GENIE: Powering Precision Medicine through an International Consortium](https://scholariq.org/papers/aacr-project-genie-powering-precision-medicine-through-an-international/)
- [Patients' Expectations about Effects of Chemotherapy for Advanced Cancer](https://scholariq.org/papers/patients-expectations-about-effects-of-chemotherapy-for-advanced-cancer/)
- [American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options](https://scholariq.org/papers/american-society-of-clinical-oncology-statement-a-conceptual-framework-to-assess/)
- [Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer](https://scholariq.org/papers/effect-of-first-line-chemotherapy-combined-with-cetuximab-or-bevacizumab-on/)
- [Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)](https://scholariq.org/papers/gemcitabine-plus-bevacizumab-compared-with-gemcitabine-plus-placebo-in-patients/)
- [Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis](https://scholariq.org/papers/moving-beyond-the-hazard-ratio-in-quantifying-the-between-group-difference-in/)
- [Adverse Symptom Event Reporting by Patients vs Clinicians: Relationships With Clinical Outcomes](https://scholariq.org/papers/adverse-symptom-event-reporting-by-patients-vs-clinicians-relationships-with/)
- [Neoadjuvant Chemotherapy Without Routine Use of Radiation Therapy for Patients With Locally Advanced Rectal Cancer: A Pilot Trial](https://scholariq.org/papers/neoadjuvant-chemotherapy-without-routine-use-of-radiation-therapy-for-patients/)
- [ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper](https://scholariq.org/papers/ctdna-applications-and-integration-in-colorectal-cancer-an-nci-colon-and-rectal/)
- [Missed Opportunities: Racial Disparities in Adjuvant Breast Cancer Treatment](https://scholariq.org/papers/missed-opportunities-racial-disparities-in-adjuvant-breast-cancer-treatment/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Economic and Financial Impacts of Cancer](https://scholariq.org/topics/economic-and-financial-impacts-of-cancer/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Cancer survivorship and care](https://scholariq.org/topics/cancer-survivorship-and-care/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

## Researcher university

- [Memorial Sloan Kettering Cancer Center](https://scholariq.org/institutions/memorial-sloan-kettering-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.